Two batches of IPS melatonin 10mg capsules recalled

Two batches of IPS melatonin 10mg capsules recalled

July 19 2018 IPS Specials is recalling two batches of its melatonin 10mg capsules, due to an...

Government considering how to implement changes to specials reimbursement

Government considering how to implement changes to specials reimbursement

May 25 2018 The government is still considering how to implement legislation passed last year...

Price of specials medicines to come under further scrutiny

Price of specials medicines to come under further scrutiny

May 9 2018 The Government says that new regulations will strengthen controls around pricing for...

Specials Drug Tariff updated for February

Specials Drug Tariff updated for February

February 2 2018 The Drug Tariffs relating to specials medicines has been updated for the February...

Special Products becomes Veriton Pharma

Special Products becomes Veriton Pharma

October 3 2017 Special Products Ltd has changed its name to Veriton Pharma Limited, to better...

  • Two batches of IPS melatonin 10mg capsules recalled

    Two batches of IPS melatonin 10mg capsules recalled

    Thursday, 19 July 2018 10:25
  • Government considering how to implement changes to specials reimbursement

    Government considering how to implement changes to specials reimbursement

    Tuesday, 29 May 2018 12:30
  • Price of specials medicines to come under further scrutiny

    Price of specials medicines to come under further scrutiny

    Wednesday, 09 May 2018 15:21
  • Specials Drug Tariff updated for February

    Specials Drug Tariff updated for February

    Friday, 02 February 2018 14:10
  • Special Products becomes Veriton Pharma

    Special Products becomes Veriton Pharma

    Tuesday, 03 October 2017 18:03

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

biodoseconnectDecember 10 2014

Quantum Pharmaceutical Group is to evaluate the role of its Biodose Connect medicines adherence device for people with dementia.

The manufacturer and supplier of niche medicines and services is teaming up with Rowlands Pharmacy and the South West Yorkshire Partnership NHS Foundation Trust to carry out the study. It will start early in January 2015 and is aiming to have 60 patients in the first cohort study.

It will “evaluate the effectiveness of using Biodose Connect with a tailored education programme to help people with dementia to independently adhere to their treatment regimen and to understand more about their medication.”

Biodose Connect has been designed to enable live, remote monitoring and management of patient adherence. It can instantly alert the patient, carer, clinician or pharmacist if medicines are not taken as prescribed. “The live monitoring of medication adherence makes it possible to quickly identify potential lapses in drug treatment regimens and deploy the appropriate intervention promptly.”

Rowlands Pharmacy’s role will be to provide an integrated Biodose Connect dispensing service with individual tailored reviews, pharmacist advice and intervention to support patients and their carers.

Professor Stephen Curran, Consultant in Old Age Psychiatry, will be evaluating the findings with Richard Clibbens, Nurse Consultant, from the South West Yorkshire Partnership NHS Foundation Trust in Wakefield.

“Poor medicines adherence for people experiencing dementia can lead to a range of difficulties. Patients can accidentally overdose, miss doses or discontinue treatment by patients without any consultation with their GP, all of which can be highly detrimental to their health and well-being and costly to the NHS and social care budgets,” said Professor Curran.

“We hear a lot about the dementia ‘time bomb’ that is about to explode but in some cases it has already gone off. The needs of people experiencing dementia are placing an increasing demand on health and social care services and the lives and finances of affected individuals and their families.”

It is estimated that 25% of beds in acute hospitals are occupied by patients with dementia and the number of people with dementia set to double in the next 30 years.

“Adherence issues may lead to avoidable and costly hospital admissions or require a full community social work and financial assessment before a package of home care is implemented.

“Often family carers or professional carers may have to visit the home a number of times each day, purely to help someone with dementia to take their medicines as prescribed, while they remain effectively independent in other areas of their life.”

The study will look at how Biodose Connect could significantly reduce these issues of poor adherence in a community setting, with the aim of preventing unnecessary, distressing and costly hospital admissions while providing better and safer outcomes for patients.

“This could also significantly delay the need for provision of costly home social care packages, maintaining the independence that most people with dementia prefer and reducing stress and burden for family carers,” added Professor Curran.

Quantum points out that the Alzheimer’s Society report ‘Dementia UK 2014’ says that dementia will affect around 850,000 people living in the UK by 2015, costing the NHS £4.3 billion. The social care budget will be an estimated £11.3 billion a year with a further £11.4 billion borne by informal family cares or people with dementia or their families paying for privately funded care.

Links:

Biodose Connect

Quantum Pharmaceutical Group

Specials News

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...